<DOC>
	<DOCNO>NCT01105273</DOCNO>
	<brief_summary>Rationale : Chemotherapy fludarabine , cyclophosphamide anti-thymocyte globulin may induce engraftment cross immunologic barrier set HLA-haploidentical allogeneic hematopoietic cell transplantation . In addition , depletion CD3±CD19 cell may contribute prevent develop severe acute graft versus host disease ( GVHD ) haploidentical transplantation . Purpose : This phase I/II trial evaluate safety efficacy fludarabine , cyclophosphamide antithymocyte globulin CD3±CD19 deplete graft haploidentical donor treat patient aplastic anemia .</brief_summary>
	<brief_title>Human Leukocyte Antigen ( HLA ) -Haploidentical Hematopoietic Stem Cell Transplantation Patients With Aplastic Anemia</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Anemia , Aplastic</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Diagnosis lifethreatening marrow failure ( severe aplastic anemia ) nonmalignant etiology meet 2 follow criterion : Granulocyte count &lt; 500/mm3 , Corrected reticulocyte count &lt; 1 % , Platelet count &lt; 20,000/mm3 No HLAidentical family member closely match ( 8 8 HLAlocus match ) unrelated marrow donor available HLAhaploidentical relate donor available Paroxysmal nocturnal hemoglobinuria Fanconi anemia Clonal cytogenetic abnormality myelodysplastic syndrome Active fungal infection HIV positive Severe disease aplastic anemia would severely limit probability survival graft procedure Pregnant nursing</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Aplastic anemia</keyword>
	<keyword>Fludarabine</keyword>
	<keyword>CD3±CD19 depletion</keyword>
	<keyword>Haploidentical hematopoietic stem cell transplantation</keyword>
</DOC>